Clinical Trial: Phase 1 Safety and Pharmacokinetics Study in Patients With Relapsed/Refractory Solid Tumors

U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07713732) titled 'Phase 1 Safety and Pharmacokinetics Study in Patients With Relapsed/Refractory Solid Tumors' on July 09.

Brief Summary: The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.

Study Start Date: July 25

Study Type: INTERVENTIONAL

Condition: Small Cell Lung Cancer ( SCLC ) Neuroendocrine Cancer Malignant Pleural Mesotheliomas (Mpm) Synovial Sarcomas

Intervention: DRUG: TLN-499

Specified dose on specified days

DRUG: Venetoclax

Specified dose on specified...